Quality Measures MIPS

Momentum is building to rethink MIPS as physician lawmakers push an overhaul of the Merit-based Incentive Payment System, reflecting continued provider frustration that quality reporting burden and payment adjustments are not reliably translating into better care or meaningful VBC incentives (Becker’s). At the same time, the quality-measure debate is broadening beyond physician reporting: AJMC’s analysis of biosimilar adoption in Medicare value-based payment models points to drug-spend stewardship as an increasingly important performance lever, while Clover’s ongoing MA Star Ratings litigation underscores how high-stakes quality measurement remains for Medicare Advantage revenue, bids, and payer-provider strategy (AJMC).